This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 09
  • /
  • Study shows no CV risk with Nesina/Vipidia for Typ...
Drug news

Study shows no CV risk with Nesina/Vipidia for Type 2D

Read time: 1 mins
Last updated:3rd Sep 2013
Published:3rd Sep 2013
Source: Pharmawand

Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV risk in Type 2 Diabetes patients at high-risk for major adverse cardiac events (MACE) due to a recent Acute Coronary Syndrome (ACS). A total of 5,380 patients were randomly assigned and followed for a median of 18 months and up to 40 months. The primary endpoint occurred at similar rates in the alogliptin and placebo groups (11.3% vs. 11.8%).

The secondary composite endpoint of CV death, myocardial infarction, stroke and unstable angina with urgent revascularization showed no difference in rates on alogliptin versus placebo (12.7% vs. 13.4%). All-cause mortality occurred in 153 patients treated with alogliptin (5.7%) and 173 patients treated with placebo (6.5%). The data, published in the New England Journal of Medicine (NEJM) are also presented at the ESC Congress 2013. See: "Alogliptin in Type 2 Diabetes" W.B. White et al. N ENg J Med September 2, 2013 DOI: 10.1056/NEJMoa1305889

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights